Vancomycin Taper vs Fidaxomicin for Recurrent C. difficile Infection (OpTION Trial): NEJM Evidence | August 2026

Introduction:

Recurrent Clostridioides difficile infection (CDI) remains a major clinical challenge, with recurrence occurring in up to one-third of patients after initial treatment. Although both vancomycin taper-and-pulse (VAN-TP) and fidaxomicin are recommended treatment options, high-quality randomized evidence directly comparing these strategies has been limited. The OpTION trial evaluated whether either approach was superior to standard 10-day vancomycin therapy in patients with first or second recurrent CDI.

Why was this study needed?

Recurrent CDI is associated with significant morbidity, repeated hospitalizations, and healthcare costs.

Current treatment recommendations are based on limited head-to-head randomized data.

Vancomycin taper-and-pulse is widely used despite limited prospective evidence.

Fidaxomicin reduces recurrence in some studies but remains costly.

Robust comparative data are needed to guide evidence-based treatment selection.

Results:

The randomized, double-blind OpTION trial enrolled 308 patients with first or second recurrent CDI.

Vancomycin taper-and-pulse achieved the highest sustained clinical response and the greatest proportion of patients remaining free from recurrent CDI compared with standard vancomycin.

Fidaxomicin demonstrated similar outcomes to standard vancomycin, without improving sustained clinical response in this study.

Although vancomycin taper showed a clinically meaningful numerical advantage, neither vancomycin taper nor fidaxomicin met the trial's predefined statistical threshold for superiority over standard vancomycin.

Overall, the findings suggest a potential benefit for vancomycin taper-and-pulse that requires confirmation in a larger adequately powered trial.

Clinical Impact:

The OpTION trial provides important randomized evidence for the management of recurrent CDI. While the study did not formally prove superiority of vancomycin taper-and-pulse, the consistent improvement in sustained response and reduction in recurrence suggests that it remains an attractive strategy for patients with recurrent disease. Unexpectedly, fidaxomicin did not outperform standard vancomycin in this trial, highlighting that treatment benefits may vary depending on the patient population and study design. Larger trials are needed before changing current guideline recommendations.

Bottom Line:

The OpTION trial did not demonstrate statistically significant superiority of either vancomycin taper-and-pulse or fidaxomicin over standard vancomycin for recurrent C. difficile infection. However, vancomycin taper-and-pulse showed the most favorable clinical outcomes and remains a promising strategy that warrants confirmation in larger randomized studies.